New perspectives in hepatocellular carcinoma surveillance after hepatitis C virus eradication
Calvin Q.Pan1
Andrew J.Park2
James S.Park3
1.Center for Liver Diseases,Guangzhou Medical Research Institute of Infectious Diseases,Guangzhou Eighth People's Hospital,Guangzhou Medical University,Guangdong,P.R.China;Division of Gastroenterology and Hepatology,Department of Medicine,NYU Grossman School of Medicine,New York,NY,USA2.Division of Hepatology,Department of Medicine,North Shore University Hospital and Donald Barbara Zucker School of Medicine at Hofstra/Northwell Health,Manhasset,NY,USA;Northwell Center for Liver Disease and Transplantation,Northwell Transplant Institute,Northwell Health,Manhasset,NY,USA;Feinstein Visiting Research Scholar Program,Feinstein Institutes for Medical Research,Manhasset,NY,USA3.Division of Hepatology,Department of Medicine,North Shore University Hospital and Donald Barbara Zucker School of Medicine at Hofstra/Northwell Health,Manhasset,NY,USA;Northwell Center for Liver Disease and Transplantation,Northwell Transplant Institute,Northwell Health,Manhasset,NY,USA
摘要：Achieving a sustained virologic response(SVR)through direct-acting antivirals for hepatitis C virus(HCV)infection significantly reduces the long-term risk of hepatocellular carcinoma(HCC),particularly in patients with advanced fibrosis(F3)or cirrhosis(F4).However,despite this improvement,the risks associated with HCC and the optimal surveillance strategies for patients who have achieved SVR remain topics of debate.This controversy is compounded by challenges in reliably staging liver fibrosis non-invasively,especially at advanced fibrosis(F3),and the unclear cost-effectiveness,modality,frequency,and duration of HCC surveillance in indi-viduals with SVR but without cirrhosis.These factors contribute to significant variations in surveillance guidelines recommended by different professional societies.Therefore,there is a pressing need for an optimal surveillance strategy that is both simplified and cost-effective to facilitate wider adoption by clinicians.This review article evaluates the existing data,addresses ongoing controver-sies,and aims to provide new perspectives on HCC surveillance strategies for patients who have achieved SVR from HCV.
机标关键词：virusaftercarcinomaeradicationhepatitishepatocellularperspectivessurveillance
论文发表日期：2024-12-30
在线出版日期：2026-07-17（本平台首次上网日期，不代表文献的发表时间）
页数：7( 568-574 )
英文信息